In Section A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Protected dosing program. Additional individuals are going to be enrolled on the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase https://peterb322ozk5.magicianwiki.com/user